Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'cdk4 inhibitor'

Search results for: 'cdk4 inhibitor'

Items 91-100 of 172

Page
per page
  1. TGX-221
    A2681 TGX-221
    Target: PI3K
    Summary: PI3Kβ inhibitor,potent,selective and ATP competitive
      insoluble in H2O; insoluble in EtOH; ≥68.7 mg/mL
  2. PF-4708671
    B2228 PF-4708671
     1 Citation
    Target: p70 rsk
    Summary: P70 S6K1 isoform inhibitor,cell-permeable
      ≥37.8 mg/mL
  3. Miltefosine
    B1371 Miltefosine
    Target: PI3K
    Summary: PI3K/Akt inhibitor
      ≥10.2 mg/mL
  4. Indirubin
    B3672 Indirubin
    Target: Cyclin-Dependent Kinases|GSK-3
    Summary: cyclin-dependent kinases and GSK-3β inhibitor
      insoluble in H2O; insoluble in H2O; insoluble in EtOH; ≥13.1 mg/mL
  5. Bikinin
    B4898 Bikinin
    Target: GSK-3
    Summary: GSK3 inhibitor and Brassinosteroid activator
      insoluble in H2O; ≥13.65 mg/mL
  6. CAL-101 (Idelalisib, GS-1101)
    A3005 CAL-101 (Idelalisib, GS-1101)
     2 Citation
    Target: PI3K
    Summary: PI3K inhibitor
  7. NVP-BGT226
    A8488 NVP-BGT226
    Target: PI3K|mTOR
    Summary: PI3K/mTOR inhibitor,selective and novel
      insoluble in EtOH; insoluble in H2O; ≥16.28 mg/mL
  8. INK 128 (MLN0128)
    A8551 INK 128 (MLN0128)
     4 Citation
    Target: mTOR
    Summary: MTOR(TORC-1/-2) inhibitor,potent and selective
      insoluble in H2O; ≥15.45 mg/mL
  9. Ridaforolimus (Deforolimus, MK-8669)
    B1639 Ridaforolimus (Deforolimus, MK-8669)
    Target: mTOR
    Summary: MTOR inhibitor
      ≥49.5 mg/mL
  10. BI-D1870
    B2227 BI-D1870
     1 Citation
    Target: p90 S6K
    Summary: P90 RSK inhibitor,ATP-competitive and cell-permeable
      insoluble in H2O; ≥19.55 mg/mL

Items 91-100 of 172

Page
per page
Shop By
Now Shopping by
  1. Category PI3K/Akt/mTOR Signaling Remove This Item
Clear All
Shopping Options
Category
  1. Akt 26item
  2. AMPK 5item
  3. CK2 8item
  4. DNA-PK 5item
  5. eNOS 2item
  6. GSK-3 17item
  7. MELK 2item
  8. mTOR 29item
  9. PI3K 60item
  10. PI4K 1 item
  11. PDK-1 8item
  12. PIKfyve 1 item
  13. PKB 1 item
  14. S6 Kinase 8item
Specificity
  1. Selective 61item
Reversibility
  1. Reversible 4item
  2. Irreversible 1 item
Target
  1. Cyclin-Dependent Kinases 2item
  2. Histone Deacetylases (HDACs) 1 item
  3. Akt 13item
  4. PI3K 35item
  5. mTOR 22item
  6. GSK-3 10item
  7. Eph Receptors 1 item
  8. VEGFR 1 item
  9. PDGFR 1 item
  10. Bcr-Abl 1 item
  11. Pim 1 item
  12. Ribosomal s6 kinases (RSK) 1 item
  13. Src 1 item
  14. DNA-PK 8item
  15. AMPK 2item
  16. S6 kinases 1 item
  17. ERK 1 item
  18. PKC 2item
  19. PKG 1 item
  20. PKA 3item
  21. MELK 1 item
  22. NUAK1 1 item
  23. NUAK2 1 item
  24. RSK 1 item
  25. ATM/ATR 2item
  26. CK2 3item
  27. HIPK2 1 item
  28. HIPK3 1 item
  29. P110 1 item
  30. Hck 1 item
  31. p70 rsk 3item
  32. PDK-1 1 item
  33. Prk 1 item
  34. NUAK 1 item
  35. NOS 1 item
  36. PIM1 kinase 1 item
  37. phospholipase A2 1 item
  38. ATM 1 item
  39. PIKfyve 1 item
  40. p90 S6K 1 item
Reported Experiments
  1. Animal Experiments 79item
  2. Cell Experiments 60item
Related Disease
  1. Adrenocortical Carcinoma 1 item
  2. Bladder Cancer 1 item
  3. Bladder Carcinoma 1 item
  4. Breast Cancer 14item
  5. Cancer 50item
  6. Cervical Cancer 1 item
  7. Cholangiocarcinoma 1 item
  8. Chronic Lymphocytic Leukemia 1 item
  9. Colon Cancer 3item
  10. Colon Carcinoma 1 item
  11. Colorectal Cancer 2item
  12. Diabetes 1 item
  13. Glioblastoma 5item
  14. Glioma 5item
  15. Hepatocellular Carcinoma 1 item
  16. Leukemia 1 item
  17. Lung Cancer 6item
  18. Melanoma 2item
  19. Neuroblastoma 2item
  20. Non-small Cell Lung Cancer 1 item
  21. Ovarian Cancer 4item
  22. Pancreatic Cancer 6item
  23. Prostate Cancer 5item
  24. Renal Cancer 1 item
  25. Rheumatoid Arthritis 1 item
  26. Type 2 Diabetes 1 item